Moleculin Biotech faces critical funding test as Annamycin’s 43% leukemia remission rate advances toward pivotal readout
PulseAI wins FDA clearance for smartwatch ECG analysis after study shows 92% fewer inconclusive results
Read More Pharma Industry News Nanyang Biologics to list via $1.5bn SPAC — What it means for The9 investors and biotech markets The9-backed Nanyang Biologics plans a $1.5B SPAC listing on Nasdaq. Find out what this means for AI drug discovery, The9’s stock, and investors. byPallavi MadhirajuOctober 2, 2025